LGALS3 and gastric cancer: In 2018, Long et al. analyzed a total of 2093 GC patients, including eight retrospective case/control studies, and found that the high expression of Gal-1 or low expression of galectins-3, -8, and -9 were significantly linked to poorer prognosis in GC patients [70].